Signal Explorer
Wednesday, September 16 · 10-K · 10-Q · 8-K · search any ticker above
28
Filings
28
Companies
0
Signals Fired
Executive Educational Background Disclosure
Top Signal
Trending Classifiers
Other
Section 409A Compliance Statement
Executive Transition Gratitude Statement
Share Withholding Tax Settlement
Non Solicitation Covenant
Other
Executive Educational Background Disclosure
Board Committee Composition Disclosure
Employee Director Compensation Waiver
Executive Transition Gratitude Statement
Other
Executive Educational Background Disclosure
Director Continuity Stated
Other
Burn Rate Controlled
Warrant Valued Black Scholes
Quarterly Tax Provision Benefit Disclosure
Quarterly Loan Deposit Growth Comparison
Share Repurchase Activity Disclosed
Deferred Tax Asset Valuation Disclosure
Depreciation Expense Composition Disclosure
Lease Rou Incremental Borrowing Rate Disclosure
Net Loss Reported
Codm Segment Reporting Disclosure
Allowance For Loan Losses Disclosure
Credit Loss Provision
Financing Activities Cash Flow Disclosure
Effective Tax Rate Reconciliation
Allowance For Credit Losses Methodology Disclosed
Other
Sanctions Compliance Representation
Restrictive Debt Covenants Disclosure
Borrower Fee Payment Obligation
Hazardous Materials Definition
Prime Rate Determination Methodology
Fcpa Compliance Representation
Libor Based Term Loan Pricing
Successor Agent Appointment Provision
Confidential Information Return Obligation
Sofr Benchmark Transition Definition
Erisa Definition Or Compliance Statement
No Regulatory Approval Required
Epa Environmental Regulation Disclosure
Closing Logistics Specified
Term Loan B Holding Disclosure
Other
Geographic Footprint Disclosure
Healthcare
Pricing Power Services
Reimbursement Improving
Volume Inflecting
Premium Pricing Power
Utilization Improving
Other
Pricing Power Expanding
Market Share Gaining
Quarterly Dividend Declared
Cash Flow Statement Investing Activities
Depreciation Expense Composition Disclosure
Related Party Loan
SaaS
Membership Growing
Deal Size Increasing
Usage Growth
Same Client Revenue Growing
Other
Share Repurchase Activity Disclosed
Other
Auditor Appointment Ratification
Auditor Change
Sec Comment Letter Response
Other
Shares Outstanding Disclosure
Sga Expense Comparison Disclosed
Lease Rou Incremental Borrowing Rate Disclosure
Other
Use Of Proceeds Disclosure
Ipo Net Proceeds Disclosure
Amendment Modification Waiver Clause
Fcpa Compliance Representation
Sanctions Compliance Representation
Exchange Offer Letter Of Transmittal
Forward Looking Statement Definition
Ipo Or Capital Raising Completion
Confidential Information Return Obligation
Core
Clinical Trial Result
Indication Expansion
Clinical Hold
Lead Asset Progress
Other
Safety Differentiated
Patient Retention High
Publication Positive
Kol Endorsement
Enrollment Ahead Of Schedule
Fda Breakthrough Device Designation
Fda Aligned
Fast Track Designation Received
Corporate Authority Representation
Healthcare
Mlr Stable
Biotech Risk
Clinical Hold Active
Other
Bitcoin Technology Description
Executive Educational Background Disclosure
Other
Auditor Appointment Ratification
Quorum Presence Disclosed
Say On Pay Vote Result Disclosed
Core
Clinical Trial Result
Lead Asset Progress
Indication Expansion
Combination Therapy Mentioned
Other
Fda Aligned
Patient Retention High
Enrollment Ahead Of Schedule
Interim Data Positive
Forward Looking Statement Definition
Expanded Access Program Active
Protocol Amended
Biotech v3
Ind Submission Planned
Other
Nasdaq Minimum Bid Price Delisting Notice
Other
Director Continuity Stated
Other
Kol Endorsement
Executive Educational Background Disclosure
Classified Board Director Election
Core
Indication Expansion
Other
Fast Track Designation Received
Fast Track Granted
Orphan Status Granted
Patent Family Portfolio Disclosure
Expanded Access Program Active
SaaS
Efficient Growth
Backlog Building
Healthcare
Same Facility Growth
Other
Demand Accelerating
Backlog Disclosure
Adjusted Ebitda Period Comparison
Merger Acquisition Synergy Benefit Claim
Order Backlog Level
Core
Clinical Trial Result
Indication Expansion
Clinical Hold
Combination Therapy Mentioned
Biotech Risk
Accelerated Approval
Other
Publication Positive
Patient Retention High
Fast Track Designation Received
Ce Mark Received
Fda Aligned
Safety Differentiated
Fda Breakthrough Device Designation
Fast Track Granted
Interim Data Positive
Other
Adjusted Ebitda Period Comparison
Merger Acquisition Synergy Benefit Claim
Other
Mineral Exploration Delineation
Earnings Call Qa Segment
Other
Quarterly Dividend Declared
Other
Nyse Listing Disclosure
Reverse Stock Split Effected
Other
Executive Transition Gratitude Statement
Core
Management Exodus
Other
Classified Board Director Election